
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9075528/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Useful and Sustainable Role for Nâ€ofâ€1 Trials in the Healthcare Ecosystem. Clinical Pharmacology and Therapeutics, 2022, 112, 224-232.	2.3	25
2	COVID-19 and climatic factors: A global analysis. Environmental Research, 2021, 193, 110355.	3.7	93
3	Assessing Cardiovascular Risk in People Living with HIV: Current Tools and Limitations. Current HIV/AIDS Reports, 2021, 18, 271-279.	1.1	24
4	Establishing the Link Between Lean Mass and Grip Strength Cut Points With Mobility Disability and Other Health Outcomes: Proceedings of the Sarcopenia Definition and Outcomes Consortium Conference. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1317-1323.	1.7	91
5	Baseline 10-Year Cardiovascular Risk Scores Predict Cognitive Function in Older Persons, and Particularly Women, Living With Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 2020, 71, 3079-3085.	2.9	11
6	The FDA and the Importance of Trust. New England Journal of Medicine, 2020, 383, e148.	13.9	10
7	Physical distancing interventions and incidence of coronavirus disease 2019: natural experiment in 149 countries. BMJ, The, 2020, 370, m2743.	3.0	427
8	Statistical inference for decision curve analysis, with applications to cataract diagnosis. Statistics in Medicine, 2020, 39, 2980-3002.	0.8	12
9	Effects of Weather on Coronavirus Pandemic. International Journal of Environmental Research and Public Health, 2020, 17, 5399.	1.2	56
10	Periodic Oscillations in Daily Reported Infections and Deaths for Coronavirus Disease 2019. JAMA Network Open, 2020, 3, e2017521.	2.8	24
11	Radiomics of Coronary Artery Calcium in the Framingham Heart Study. Radiology: Cardiothoracic Imaging, 2020, 2, e190119.	0.9	22
12	Review of current advances in survival analysis and frailty models. Wiley Interdisciplinary Reviews: Computational Statistics, 2020, 12, e1504.	2.1	5
13	Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19. New England Journal of Medicine, 2020, 382, 2462-2464.	13.9	107
14	Prediction Models — Development, Evaluation, and Clinical Application. New England Journal of Medicine, 2020, 382, 1583-1586.	13.9	77
15	Application of net reclassification index to non-nested and point-based risk prediction models: a review. European Heart Journal, 2019, 40, 1880-1887.	1.0	39
16	New Guidelines for Statistical Reporting in the <i>Journal</i> . New England Journal of Medicine, 2019, 381, 285-286.	13.9	233
17	Measures for evaluation of prognostic improvement under multivariate normality for nested and nonnested models. Statistics in Medicine, 2019, 38, 3817-3831.	0.8	6
18	Density and morphology of coronary artery calcium for the prediction of cardiovascular events: insights from the Framingham Heart Study. European Radiology, 2019, 29, 6140-6148.	2.3	15

#	Article	IF	CITATIONS
19	Association of an HDL Apolipoproteomic Score With Coronary Atherosclerosis and Cardiovascular Death. Journal of the American College of Cardiology, 2019, 73, 2135-2145.	1.2	26
20	Widespread pain is a risk factor for cardiovascular mortality: results from the Framingham Heart Study. European Heart Journal, 2019, 40, 1609-1617.	1.0	44
21	Evaluating classification accuracy for modern learning approaches. Statistics in Medicine, 2019, 38, 2477-2503.	0.8	37
22	Blood kidney injury molecule–1 predicts short and longer term kidney outcomes in patients undergoing diagnostic coronary and/or peripheral angiography—Results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study. American Heart Journal, 2019, 209, 36-46.	1.2	9
23	Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies. European Heart Journal, 2019, 40, 621-631.	1.0	97
24	Singleâ€number summary and decision analytic measures can happily coexist. Statistics in Medicine, 2019, 38, 499-500.	0.8	1
25	Efficacy and Effectiveness Too Trials: Clinical Trial Designs to Generate Evidence on Efficacy and on Effectiveness in Wide Practice. Clinical Pharmacology and Therapeutics, 2019, 105, 857-866.	2.3	17
26	Quantifying Importance of Major Risk Factors for Coronary Heart Disease. Circulation, 2019, 139, 1603-1611.	1.6	115
27	Cardiac Abnormalities in Patients With Hutchinson-Gilford Progeria Syndrome. JAMA Cardiology, 2018, 3, 326.	3.0	67
28	Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome. JAMA - Journal of the American Medical Association, 2018, 319, 1687.	3.8	159
29	Cardiovascular Risk Prediction Functions Underestimate Risk in HIV Infection. Circulation, 2018, 137, 2203-2214.	1.6	151
30	Survey of plasma proteins in children with progeria pre-therapy and on-therapy with lonafarnib. Pediatric Research, 2018, 83, 982-992.	1.1	11
31	Pubertal Progression in Female Adolescents with Progeria. Journal of Pediatric and Adolescent Gynecology, 2018, 31, 238-241.	0.3	6
32	External validation of the TIMI risk score for secondary cardiovascular events among patients with recent myocardial infarction. Atherosclerosis, 2018, 272, 80-86.	0.4	24
33	Fracture Risk Assessment in Long-term Care (FRAiL): Development and Validation of a Prediction Model. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 763-769.	1.7	37
34	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet, The, 2018, 392, 1519-1529.	6.3	1,179
35	Microsimulation model to predict incremental value of biomarkers added to prognostic models. Journal of the American Medical Informatics Association: JAMIA, 2018, 25, 1382-1385.	2.2	2
36	Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—Rationale, design, and baseline characteristics. American Heart Journal, 2018, 203, 30-38.	1.2	51

#	Article	IF	CITATIONS
37	International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Postâ€MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee. Journal of the American Heart Association, 2018, 7, .	1.6	17
38	Revised Framingham Stroke Risk Profile to Reflect Temporal Trends. Circulation, 2017, 135, 1145-1159.	1.6	142
39	Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). Circulation, 2017, 135, 1720-1732.	1.6	17
40	Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials. Statistics in Medicine, 2017, 36, 1334-1360.	0.8	42
41	Relation of Risk Factors and Abdominal Aortic Calcium to Progression of Coronary Artery Calcium (from the Framingham Heart Study). American Journal of Cardiology, 2017, 119, 1584-1589.	0.7	21
42	Challenges in the Design and Interpretation of Noninferiority Trials. New England Journal of Medicine, 2017, 377, 1357-1367.	13.9	233
43	Association of Multiorgan Computed Tomographic Phenomap With Adverse Cardiovascular Health Outcomes. JAMA Cardiology, 2017, 2, 1236.	3.0	19
44	Coronary Artery Calcium Distribution Is an Independent Predictor of Incident Major Coronary Heart Disease Events. Circulation: Cardiovascular Imaging, 2017, 10, .	1.3	78
45	Increased Aortic Diameters on Multidetector Computed Tomographic Scan Are Independent Predictors of Incident Adverse Cardiovascular Events. Circulation: Cardiovascular Imaging, 2017, 10, .	1.3	27
46	Authors' response to comments. Statistics in Medicine, 2017, 36, 4511-4513.	0.8	3
47	Asymptotic distribution of â^†AUC, NRIs, and IDI based on theory of Uâ€ s tatistics. Statistics in Medicine, 2017, 36, 3334-3360.	0.8	20
48	Net reclassification index at event rate: properties and relationships. Statistics in Medicine, 2017, 36, 4455-4467.	0.8	70
49	Incident Type 2 Myocardial Infarction in a Cohort of Patients Undergoing Coronary or Peripheral Arterial Angiography. Circulation, 2017, 135, 116-127.	1.6	90
50	Guideline-Based Statin Eligibility, Cancer Events, and Noncardiovascular Mortality in the Framingham Heart Study. Journal of Clinical Oncology, 2017, 35, 2927-2933.	0.8	22
51	Developing pointsâ€based riskâ€scoring systems in the presence of competing risks. Statistics in Medicine, 2016, 35, 4056-4072.	0.8	87
52	Cardiovascular Event Prediction and Risk Reclassification by Coronary, Aortic, and Valvular Calcification in the Framingham Heart Study. Journal of the American Heart Association, 2016, 5, .	1.6	150
53	Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood, 2016, 127, 1656-1665.	0.6	255
54	No One Size Fits All. Journal of the American College of Cardiology, 2016, 68, 636-638.	1.2	0

#	Article	IF	CITATIONS
55	Lung Cancer Screening Eligibility in the Community. Circulation, 2016, 134, 897-899.	1.6	16
56	Temporal Changes in the Association Between Modifiable Risk Factors and Coronary Heart Disease Incidence. JAMA - Journal of the American Medical Association, 2016, 316, 2041.	3.8	30
57	Circulating Proneurotensin Concentrations and Cardiovascular Disease Events in the Community. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1692-1697.	1.1	50
58	Carotid Atherosclerosis and Cerebral Microbleeds: The Framingham Heart Study. Journal of the American Heart Association, 2016, 5, e002377.	1.6	41
59	Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-term Phase IV PREVAIL US Trial in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia. Clinical Therapeutics, 2016, 38, 603-609.	1.1	12
60	Association of Maternal Prepregnancy Dyslipidemia With Adult Offspring Dyslipidemia in Excess of Anthropometric, Lifestyle, and Genetic Factors in the Framingham Heart Study. JAMA Cardiology, 2016, 1, 26.	3.0	38
61	Circulating Sex Steroids and Vascular Calcification in Community-Dwelling Men: The Framingham Heart Study. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2160-2167.	1.8	20
62	Fiveâ€Year Risk of Mechanical Ventilation in Communityâ€Dwelling Adults: The Framingham–Intermountain Anticipating Life Support Study. Journal of the American Geriatrics Society, 2015, 63, 2082-2088.	1.3	4
63	Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. European Journal of Preventive Cardiology, 2015, 22, 1321-1327.	0.8	112
64	The Role of Physicians in the Era of Predictive Analytics. JAMA - Journal of the American Medical Association, 2015, 314, 25.	3.8	55
65	Guideline-Based Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events. JAMA - Journal of the American Medical Association, 2015, 314, 134.	3.8	118
66	Using Age- and Sex-Specific Risk Thresholds to Guide Statin Therapy. Journal of the American College of Cardiology, 2015, 65, 1633-1639.	1.2	58
67	Duration and Degree of Weight Gain and Incident Diabetes in Younger Versus Middle-Aged Black and White Adults: ARIC, CARDIA, and the Framingham Heart Study. Diabetes Care, 2015, 38, 2042-2049.	4.3	32
68	Evaluating Discrimination of Risk Prediction Models. JAMA - Journal of the American Medical Association, 2015, 314, 1063.	3.8	268
69	Autonomic Imbalance as a Predictor of Metabolic Risks, Cardiovascular Disease, Diabetes, and Mortality. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2443-2448.	1.8	177
70	Risk Prediction for Individuals—Reply. JAMA - Journal of the American Medical Association, 2015, 314, 1875.	3.8	2
71	Long-term risk of cardiovascular events across a spectrum of adverse major plasma lipid combinations in the Framingham Heart Study. American Heart Journal, 2014, 168, 878-883.e1.	1.2	58
72	Risk Estimation for Recurrent Clostridium difficile Infection Based on Clinical Factors. Clinical Infectious Diseases, 2014, 58, 1386-1393.	2.9	70

#	Article	IF	CITATIONS
73	Quantifying Cardiometabolic Risk Using Modifiable Non–Self-Reported Risk Factors. American Journal of Preventive Medicine, 2014, 47, 131-140.	1.6	13
74	Impact of Farnesylation Inhibitors on Survival in Hutchinson-Gilford Progeria Syndrome. Circulation, 2014, 130, 27-34.	1.6	186
75	Biomarkers of Cardiovascular Stress and Subclinical Atherosclerosis in the Community. Clinical Chemistry, 2014, 60, 1402-1408.	1.5	24
76	Left Ventricular Hypertrophy Patterns and Incidence of Heart Failure With Preserved Versus Reduced Ejection Fraction. American Journal of Cardiology, 2014, 113, 117-122.	0.7	103
77	One-Year Outcomes of Out-of-Hospital Administration of Intravenous Glucose, Insulin, and Potassium (GIK) in Patients With Suspected Acute Coronary Syndromes (from the IMMEDIATE [Immediate) Tj ETQq1 1 0.784 American lournal of Cardiology, 2014, 113, 1599-1605.	4314 rgBT 0.7	/gyerlock 1
78	Cardiovascular Disease Risk Assessment: Insights from Framingham. Global Heart, 2013, 8, 11.	0.9	200
79	Invited Commentary: Clinical Usefulness of the Framingham Cardiovascular Risk Profile Beyond Its Statistical Performance. American Journal of Epidemiology, 2012, 176, 187-189.	1.6	10
80	Cardiovascular Risk Estimation in 2012: Lessons Learned and Applicability to the HIV Population. Journal of Infectious Diseases, 2012, 205, S362-S367.	1.9	62
81	Changing End Points in Breast-Cancer Drug Approval — The Avastin Story. New England Journal of Medicine, 2011, 365, e2.	13.9	67
82	Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Stem Cell Transplant (SCT) and Non-SCT Patients (Pts): Early Intervention Improves Outcome - Updated Results of a Treatment IND Expanded Access Protocol. Blood, 2011, 118, 487-487.	0.6	3
83	The Delayed-Start Study Design. New England Journal of Medicine, 2009, 361, 1304-1306.	13.9	106
84	Carbohydrateâ€related dietary factors and plasma adiponectin levels in healthy adults in the Framingham Offspring Cohort FASEB Journal, 2009, 23, 229.5.	0.2	2
85	General Cardiovascular Risk Profile for Use in Primary Care. Circulation, 2008, 117, 743-753.	1.6	5,601
86	Response to Letter Regarding Article, "Use of Alternative Thresholds Defining Insulin Resistance to Predict Incident Type 2 Diabetes Mellitus and Cardiovascular Disease― Circulation, 2008, 118, .	1.6	0
87	The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: Design, Recruitment, and Initial Examination. American Journal of Epidemiology, 2007, 165, 1328-1335.	1.6	752
88	Clinical Correlates and Heritability of Vitamins K and D. FASEB Journal, 2007, 21, A174.	0.2	1
89	Inference on Correlated Discrimination Measures in Survival Analysis: A Nonparametric Approach. Communications in Statistics - Theory and Methods, 2004, 33, 2117-2135.	0.6	61
90	Clinical and microbial evaluation of a histatin-containing mouthrinse in humans with experimental gingivitis. Journal of Clinical Periodontology, 2001, 28, 404-410.	2.3	37

#	Article	IF	CITATIONS
91	ROBUSTNESS AND POWER OF ANALYSIS OF COVARIANCE APPLIED TO DATA DISTORTED FROM NORMALITY BY FLOOR EFFECTS: HOMOGENEOUS REGRESSION SLOPES. , 1996, 15, 477-496.		20
92	Stroke Severity in Atrial Fibrillation. Stroke, 1996, 27, 1760-1764.	1.0	1,122
93	Meta-analysis: A method for synthesizing research*. Clinical Pharmacology and Therapeutics, 1995, 58, 605-616.	2.3	65
94	Age-adjusted survival curves with application in the Framingham study. Statistics in Medicine, 1995, 14, 1731-1744.	0.8	57
95	Development of health risk appraisal functions in the presence of multiple indicators: The Framingham Study nursing home institutionalization model. Statistics in Medicine, 1995, 14, 1757-1770.	0.8	23
96	A technique for summarizing longitudinal data. Statistics in Medicine, 1993, 12, 2169-2178.	0.8	12
97	Discussion: Logical and analytical issues in dental/oral product comparison research. Journal of Periodontal Research, 1992, 27, 349-351.	1.4	5
98	Anticalculus effect of a dentifrice containing 0.5% zinc citrate trihydrate. Community Dentistry and Oral Epidemiology, 1991, 19, 29-31.	0.9	16
99	Multiple comparisons in over-the-ounter drug clinical trials with both positive and placebo controls. Statistics in Medicine, 1991, 10, 1-6.	0.8	49
100	Relation of pooled logistic regression to time dependent cox regression analysis: The framingham heart study. Statistics in Medicine, 1990, 9, 1501-1515.	0.8	681
101	A Suggestion for Using Powerful and Informative Tests of Normality. American Statistician, 1990, 44, 316-321.	0.9	960
102	Comparison of baseline and repeated measure covariate techniques in the Framingham heart study. Statistics in Medicine, 1988, 7, 205-218.	0.8	228
103	The Appropriateness of Some Common Procedures for Testing the Equality of Two Independent Binomial Populations. American Statistician, 1988, 42, 198-202.	0.9	128
104	Need and Possibilities for Research. Emergency Health Services Review, 1983, 2, 61-63.	0.0	0
105	The logistic function as an aid in the detection of acute coronary disease in emergency patients (A) Tj ETQq1 1 0.	784314 rg 0.8	gBT_/Overloci
106	Robustness of Location Estimators under Changes of Population Kurtosis. Journal of the American Statistical Association, 1977, 72, 393-396.	1.8	15
107	Linear Estimation of the Logistic Parameters for Complete or Tail-Censored Samples. Journal of the American Statistical Association, 1976, 71, 462-464.	1.8	3
108	On the Evaluation of the Kolmogorov Statistic. American Statistician, 1973, 27, 81-82.	0.9	3

#	Article	IF	CITATIONS
109	A Class of Simple Linear Estimators of the Standard Deviation of the Normal Distribution. Journal of the American Statistical Association, 1973, 68, 207-210.	1.8	12
110	A Class of Simple Linear Estimators of the Standard Deviation of the Normal Distribution. , 0, .		2
111	Linear Estimation of the Logistic Parameters for Complete or Tail-Censored Samples. , 0, .		1
112	Robustness of Location Estimators under Changes of Population Kurtosis. , 0, .		3